CD14 and neoplasm: The CD14+ cDC2 population, previously identified in tumor settings as cDC2/moDCs, is also detected in melanoma lesions, characterized by immunosuppressive function and higher expression of additional macrophage-like markers (CD163, CD206, MerTK) and PD-L1 in comparison to CD14− cDC2s [233].